Payment overview · 2025
General Payments
$118.80
7 reported records · 6 companies
Healthcare provider profile · identity verified
Michael Alan Caplan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DANVILLE, VA · NPI 1275572562
Verified facts
What the public records show
CMS Open Payments records show Michael Alan Caplan, MD received $118.80 in general payments during 2025 across 7 reported records.
Corcept Therapeutics accounted for 31.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $37.41 | 31.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.46 | 15.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.35 | 13.8% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.96 | 13.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.92 | 13.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.70 | 12.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $118.80 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $37.41 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 149 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
149 | 28 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1116 | 294 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1101 | 302 |
| Losartan Potassium | Losartan Potassium | 920 | 235 |
| Levothyroxine Sodium | Levothyroxine Sodium | 532 | 137 |
| Metoprolol Succinate | Metoprolol Succinate | 489 | 142 |
| Metformin Hcl | Metformin Hcl | 480 | 139 |
| Omeprazole | Omeprazole | 459 | 131 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 451 | 125 |
| Hydrochlorothiazide | Hydrochlorothiazide | 423 | 113 |
| Ezetimibe | Ezetimibe | 422 | 123 |
| Simvastatin | Simvastatin | 384 | 104 |
| Pantoprazole Sodium | Pantoprazole Sodium | 362 | 109 |
| Tamsulosin Hcl | Tamsulosin Hcl | 267 | 76 |
| Gabapentin | Gabapentin | 247 | 49 |
| Spironolactone | Spironolactone | 229 | 70 |
| Montelukast Sodium | Montelukast Sodium | 203 | 52 |
| Eliquis | Apixaban | 196 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 189 | 53 |
| Ozempic | Semaglutide | 183 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 171 | 42 |
| Allopurinol | Allopurinol | 169 | 41 |
| Lisinopril | Lisinopril | 168 | 49 |
| Trulicity | Dulaglutide | 162 | 25 |
| Farxiga | Dapagliflozin Propanediol | 160 | 35 |
| Trazodone Hcl | Trazodone Hcl | 160 | 54 |
| Furosemide | Furosemide | 157 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 154 | 44 |
| Prednisone | Prednisone | 151 | 43 |
| Jardiance | Empagliflozin | 149 | 28 |
| Alprazolam | Alprazolam | 146 | 20 |
| Meloxicam | Meloxicam | 146 | 44 |
| Xarelto | Rivaroxaban | 139 | 27 |
| Alendronate Sodium | Alendronate Sodium | 133 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 55 |
| Baclofen | Baclofen | 130 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 36 |
| Terazosin Hcl | Terazosin Hcl | 127 | 31 |
| Irbesartan | Irbesartan | 124 | 28 |
| Carvedilol | Carvedilol | 115 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 115 | 27 |
| Potassium Chloride | Potassium Chloride | 115 | 30 |
| Sertraline Hcl | Sertraline Hcl | 114 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 29 |
| Valsartan | Valsartan | 113 | 32 |
| Metformin Hcl Er | Metformin Hcl | 108 | 28 |
| Lorazepam | Lorazepam | 107 | 16 |
| Famotidine | Famotidine | 106 | 29 |
| Buspirone Hcl | Buspirone Hcl | 104 | 28 |
| Celecoxib | Celecoxib | 97 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 96 | 27 |
| Fenofibrate | Fenofibrate | 92 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 92 | 24 |
| Glimepiride | Glimepiride | 90 | 26 |
| Synthroid | Levothyroxine Sodium | 90 | 21 |
| Finasteride | Finasteride | 86 | 27 |
| Mirtazapine | Mirtazapine | 86 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 24 |
| Vascepa | Icosapent Ethyl | 81 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 75 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 74 | 18 |
| Memantine Hcl | Memantine Hcl | 74 | 12 |
| Januvia | Sitagliptin Phosphate | 73 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 17 |
| Bupropion Xl | Bupropion Hcl | 65 | 18 |
| Clonazepam | Clonazepam | 65 | 12 |
| Repatha Sureclick | Evolocumab | 65 | 12 |
| Torsemide | Torsemide | 59 | 16 |
| Donepezil Hcl | Donepezil Hcl | 57 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 16 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 52 | 17 |
| Meclizine Hcl | Meclizine Hcl | 52 | 22 |
| Rybelsus | Semaglutide | 51 | suppressed |
| Primidone | Primidone | 50 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 24 |
| Colesevelam Hcl | Colesevelam Hcl | 46 | suppressed |
| Methotrexate | Methotrexate Sodium | 45 | 11 |
| Pregabalin | Pregabalin | 43 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 17 |
| Telmisartan | Telmisartan | 42 | 12 |
| Atenolol | Atenolol | 40 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 40 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 39 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | suppressed |
| Lansoprazole | Lansoprazole | 38 | suppressed |
| Lovastatin | Lovastatin | 38 | suppressed |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | 11 |
| Clotrimazole | Clotrimazole | 32 | suppressed |
| Rexulti | Brexpiprazole | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Ketoconazole | Ketoconazole | 30 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Gemtesa | Vibegron | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Kerendia | Finerenone | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 15 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 19 |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 19 |
| Colchicine | Colchicine | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 18 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Novolog | Insulin Aspart | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Glipizide Er | Glipizide | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Benzonatate | Benzonatate | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Exforge | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $118.80 · 7 records | Corcept Therapeutics | JARDIANCE, Korlym, LEQVIO, NUZYRA, OTEZLA, REPATHA, XIFAXAN | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error